Ads
related to: why is simvastatin prescribed for pain reviews and problems symptoms
Search results
Results From The WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels . [ 4 ]
SAAM may affect people after long-term statin use even if they had no previous muscular side effects. [4] A differentiating feature between this and more benign statin side effects is SAAM typically has a late onset. While muscle pain (myalgia) is seen in 9-20% of patients treated with statins, it typically occurs in the first month of treatment.
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
Muscle pain and other symptoms often cause patients to stop taking a statin. [88] This is known as statin intolerance. A 2021 double-blind multiple crossover randomized controlled trial (RCT) in statin-intolerant patients found that adverse effects, including muscle pain, were similar between atorvastatin and placebo. [ 89 ]
Statin-induced hepatotoxicity can cause autoimmune hepatitis and an elevation in serum levels of hepatic enzymes such as alanine aminotransferase, impairing liver function. [20] Myotoxicity is commonly presented with statin-associated muscle symptoms (SAMS), which include myalgia and myositis. [21]
Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred. No mutagenic effects were seen in assays.
Myalgia or muscle pain is a painful sensation evolving from muscle tissue. It is a symptom of many diseases . The most common cause of acute myalgia is the overuse of a muscle or group of muscles ; another likely cause is viral infection , especially when there has been no injury .
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]